2TZ Stock Chart & Stats
€2.72
>-€0.01(-0.15%)
At close: 4:00 PM EST
€2.72
>-€0.01(-0.15%)
Day’s Range― - ―
52-Week Range€2.10 - €3.15
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€3.10B
Enterprise Value€1.62K
Total Cash (Recent Filing)€3.53B
Total Debt (Recent Filing)€98.38M
Price to Earnings (P/E)33.0
Beta0.04
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.10
Shares Outstanding200,000,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.92
Price to Book (P/B)2.58
Price to Sales (P/S)3.73
P/FCF Ratio53.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.18
Revenue Forecast (FY)€648.01M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageExtremely low debt reduces refinancing and solvency risk, preserving capacity to fund operations, product development and distributions through weaker cycles. Solid equity and positive returns add resilience without dependence on leverage.
Positive Cash GenerationPositive TTM operating and free cash flow, with FCF at about 87% of net income, supports earnings quality and internal funding. This gives the group resources for working capital, investment and shareholder returns, although timing varies.
Strong ProfitabilityTTM gross and net margins of about 74% and 18% indicate meaningful profitability in the pharmaceutical portfolio. A high-margin base can support reinvestment and absorb some cost pressure, even as current earnings have weakened.
Bears Say
Revenue ContractionTTM revenue is contracting, while the broader revenue-growth measure is negative. Persistent top-line pressure would constrain operating leverage, distribution scale and the funds available for product investment.
Sharp Earnings DeclineNet income has fallen sharply versus 2024–2025 and EPS growth is down about 74.8%, indicating reduced earnings power despite healthy margins. This volatility makes future reinvestment and payout capacity less predictable.
Uneven Cash ConversionCash conversion is uneven across years, and TTM operating cash flow is about 19.8% of revenue. Working-capital or timing volatility can make internally generated funds less predictable for expansion and shareholder returns.
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S News
2TZ FAQ
What was Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s price range in the past 12 months?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S lowest stock price was €2.10 and its highest was €3.15 in the past 12 months.
What is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s market cap?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s market cap is €3.10B.
When is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s upcoming earnings report date?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s upcoming earnings report date is Nov 04, 2026 which is in 66 days.
How were Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s earnings last quarter?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S released its earnings results on Aug 14, 2026. The company reported €0.036 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S overvalued?
According to Wall Street analysts Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s price is currently Overvalued.
Does Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S pay dividends?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S does not currently pay dividends.
What is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s EPS estimate?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S have?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S has 200,000,000 shares outstanding.
What happened to Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s price movement after its last earnings report?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S reported an EPS of €0.036 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.739%.
Which hedge fund is a major shareholder of Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S?
Currently, no hedge funds are holding shares in DE:2TZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S Stock Smart Score
Company Description
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (TPDRTG), a prominent pharmaceutical group operating with its various subsidiaries, primarily serves the People's Republic of China. Its core focus lies in the production and sale of traditional Chinese medicines, Western pharmaceuticals, and health-related products. The company's operations are distinctly divided into two key segments: Chinese Medicine and Western Medicine. Beyond manufacturing, TPDRTG is actively involved in the development and commercialization of both traditional Chinese and Western pharmaceutical and biological items. It also maintains and operates hospitals, alongside running extensive wholesale and retail networks for various medicines, biochemical products, and everyday consumer goods. Furthermore, TPDRTG extends its operations to include a suite of services such as logistics, inventory management, equipment installation, specialized medicine processing, inspection and testing, and pharmaceutical consultancy. The company's commercial strategy involves both the direct supply of its proprietary branded medicinal products to wholesalers, and acting as an intermediary to distribute third-party medicinal products to other wholesalers. Established in 1992, the company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, adopting its current name in May 2022. It is headquartered in Tianjin, People's Republic of China.
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (2TZ) Earnings & Revenues
Technical Analysis
Hyphens Pharma International Ltd.
―
iX Biopharma Ltd.
―
Medtecs International Corporation Ltd.
―
Biolidics Ltd.
―
Pharmesis International Ltd.
―